TKTari A. King

Tari A. King

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tari A. King has a total of 499 co-authors. Here are the top co-authors by number of shared publications:

  • Elizabeth A. Mittendorf

    Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA

    22 shared publications
  • Alison Laws

    Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA

    20 shared publications
  • Olga Kantor

    Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA

    16 shared publications
  • Anna Weiss

    Department of Surgery, University of Rochester Medical Center, Rochester, USA

    13 shared publications
  • Monica Morrow

    12 shared publications
  • Faina Nakhlis

    Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA

    11 shared publications

Latest Publications

  • Active Surveillance for Atypical Ductal Hyperplasia: Are We Ready for Surgical De-escalation?

    by Alison Laws, Tari A. King

    Atypical ductal hyperplasia (ADH) remains one of the few benign breast lesions for which surgical excision is routinely recommended because of the risk of underlying carcinoma, most commonly ductal carcinoma in situ (DCIS). However, increasing interest in active surveillance has emerged alongside broader trends toward surgical de-escalation and ongoing prospective trials evaluating observation for low-risk DCIS. In this commentary, we review the challenges of identifying patients with ADH at sufficiently low risk of upgrade and summarize emerging outcome data supporting active monitoring. We discuss the target trial emulation study by Rangel and colleagues, evaluating active monitoring versus surgical excision for selected patients with ADH, as well as novel tools that may further support this approach. Together, these developments suggest a growing role for individualized management strategies in ADH. See related article by Rangel et al., p. 577

  • Worsening frailty and declining quality of life in older survivors of nonmetastatic breast cancer

    by Christina A Minami, Leah R Jager, Eliza H Lorentzen, Aladdin H Shadyab, Jessica L Krok-Schoen, Abu Taiyab Nazmus Saquib, Jennifer J King, Garnet L Anderson, Tari A King, Elizabeth A Mittendorf

    Breast cancer treatment can worsen frailty, but the impact of this decline on long-term quality of life remains uncertain. We identified women 65 years of age and older with nonmetastatic breast cancer from the Life and Longevity After Cancer survivorship cohort of the Women’s Health Initiative. We examined the association between clinically significant worsening of frailty, measured by a validated claims-based index 1 year after diagnosis, and long-term decline in quality of life, assessed using a 10-point scale 4-6 years after diagnosis. Among 1061 eligible patients, 692 (65.2%) were robust (not living with frailty), 343 (32.3%) were living with prefrailty, and 26 (2.5%) were living with frailty at cancer diagnosis. Clinically significant worsening of frailty occurred in 19.5% of patients. In fully adjusted models, worsening frailty was statistically significantly associated with long-term quality of life declines (odds ratio = 1.48, 95% CI = 1.07 to 2.04). These findings highlight the need for interventions to prevent worsening frailty during breast cancer treatment.

  • Open Access

    Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies

    by Stefania Morganti, Se E Kim, Qingchun Jin, Jaeyoon Cha, Jacqueline E Zeigler, Alexandra B Newman, Gregory J Kirkner, Craig Snow, Yue Zheng, Julie Vincuilla, et al.

    Background: Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features. Methods: We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women’s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers. Results: Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P < .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P < .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P < .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences. Conclusions: We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.

  • Open Access

    Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer

    by Jorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, Alice M. Barkell, John Navarro, Lan Ngo, Ayesha Mohammed-Abreu, Verena M. Prade, Ina Bisha, Sudhanshu Abhishek, et al.

    Introduction: With recent approvals of multiple targeted therapies for triple-negative breast cancer (TNBC), including antibody-drug conjugates and immunotherapy in biomarker-selected populations, it is critical to define the temporal evolution of cell-surface target expression from early-stage to metastatic disease, the co-expression patterns across these markers, and optimal quantification methodologies. Here we report biomarker expression profiles measured by multi-omics and pathology-based platforms in patients with TNBC using a large cohort of matched longitudinal tumor samples. Methods: Patients who underwent neoadjuvant chemotherapy (NAC) for stage I-III TNBC or were diagnosed with any stage TNBC and developed metastatic recurrence were retrospectively identified from an institutional database and prospective research metastatic biopsy protocol. Tumor samples from diagnosis (DX), residual disease (RD) post-NAC (if applicable), and metastasis/recurrence (MR) were collected. Quantification of HER2, TROP2, and PD-L1 expression was performed by immunohistochemistry (IHC), whole-exome sequencing, transcriptome sequencing, and targeted mass spectrometry (MS). For HER2, TROP2, and stromal tumor-infiltrating lymphocytes (sTILs), both manual pathologist assessment and computational pathology quantification were obtained. HER2 status was categorized as HER2-0 or HER2-low by local (L-IHC) and central (C-IHC) review, TROP2 status was defined as low (H-score 200), and PD-L1 as low (tumor area positivity, TAP ERBB2 , TACSTD2 and CD274 mRNA expression were significantly correlated with IHC protein levels, though only TACSTD2 had limited overlap in distribution of gene expression between high/medium vs low groups. Strong correlation between protein membrane staining intensity from computational pathology, protein expression measured by MS, and pathologist-assed IHC was observed across all biomarkers tested by each method. In comparisons between biomarkers, pathologist-assessed PD-L1 IHC and sTILs were significantly correlated (p=0.0001); 94% (51/54) of PD-L1-high tumors were classified as sTILs high/medium. PAM50 subtype was not significantly correlated with time point or biomarker status, although there was a trend toward more HER2-enriched tumors in HER2-low (20%, 5/25) vs HER2-0 (6%, 3/52) (p=0.086). Across biomarkers and clinical variables, an association between age and sTILs was observed (p=0.038, FDR=0.42) due to a decrease in sTILs high/medium tumors with age, primarily driven by post-treatment (RD/MR) but not DX samples. Conclusions: Multi-platform and multi-omics profiling in this large unique cohort of longitudinal TNBC samples revealed distinct patterns of expression and dynamic changes of key biomarkers of interest for targeted therapies. Given variability with manual IHC scoring, improved methods for quantification of expression may help optimize treatment selection in an individualized manner.

  • Open Access

    Supplementary Figure S3 from Clinicogenomic Characterization of Inflammatory Breast Cancer

    by Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E. Hughes, Yvonne Li, Alinés Lebrón-Torres, Gregory J. Kirkner, Liam F. Spurr, Marie Claire Remolano, Sarah Strauss, et al.

    Supplementary Figure S3. Expression of TP53 in IBC vs non-IBC.

  • Open Access

    Supplementary Figure S4 from Clinicogenomic Characterization of Inflammatory Breast Cancer

    by Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E. Hughes, Yvonne Li, Alinés Lebrón-Torres, Gregory J. Kirkner, Liam F. Spurr, Marie Claire Remolano, Sarah Strauss, et al.

    Supplementary Figure S4. Days on CDK4/6i therapy by presence or absence of CCND1 amplification orTP53 alteration.

  • Open Access

    Supplementary Tables S1-S15 from Clinicogenomic Characterization of Inflammatory Breast Cancer

    by Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E. Hughes, Yvonne Li, Alinés Lebrón-Torres, Gregory J. Kirkner, Liam F. Spurr, Marie Claire Remolano, Sarah Strauss, et al.

    Supplementary Tables S1-S15 from Clinicogenomic Characterization of Inflammatory Breast Cancer

  • Open Access

    Supplementary Figure S1 from Clinicogenomic Characterization of Inflammatory Breast Cancer

    by Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E. Hughes, Yvonne Li, Alinés Lebrón-Torres, Gregory J. Kirkner, Liam F. Spurr, Marie Claire Remolano, Sarah Strauss, et al.

    Supplementary Figure S1. Landscape of TP53 alterations in IBC.

  • Open Access

    Supplementary Figure S2 from Clinicogenomic Characterization of Inflammatory Breast Cancer

    by Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa E. Hughes, Yvonne Li, Alinés Lebrón-Torres, Gregory J. Kirkner, Liam F. Spurr, Marie Claire Remolano, Sarah Strauss, et al.

    Supplementary Figure S2. Notch signaling pathway activation in IBC vs non-IBC; including HER2+ subset.

  • Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic

    by Alexandra Wehbe, Fisher Katlin, Eshita Sharma, Marybeth Hans, Mary Knust Graichen, Brittany L. Bychkovsky, Rochelle Scheib, Judy E. Garber, Lydia E. Pace, Tari A. King, et al.

    Purpose The National Comprehensive Cancer Network (NCCN) and American Cancer Society (ACS) endorse differing guidelines for screening breast imaging among young females with familial breast cancer risk not driven by a germline pathogenic variant (PV). We sought to characterize practice patterns in our high-risk breast clinic related to screening breast imaging in this population. Methods We identified all females aged 25–39 years with a first- or second-degree relative (FDR/SDR) with breast cancer and estimated lifetime breast cancer risk of ≥ 20% by the Tyrer-Cuzick (TC) version 7 model. Those with known PV in a breast cancer gene were excluded. We described provider recommendations for age to initiate screening and use of supplemental imaging modalities. Results Among 334 included patients, 218 (65.3%) had an FDR with breast cancer and 116 (34.7%) had SDRs only. Screening prior to age 40 was recommended to 233 (69.8%) patients and varied by extent of family history and age of the youngest affected relative. Only a minority (24.1–27.0%) of recommendations aligned with NCCN or ACS guidelines. For the remaining patients, 82.2% and 48.7% were recommended to initiate screening younger than the NCCN or ACS guideline, respectively. Supplemental imaging with MRI or whole breast ultrasound was offered to 219 (65.6%) patients. Conclusion Even in a specialized clinic, there is substantial variation in breast imaging recommendations for young females with elevated breast cancer risk based on family history. As formal risk assessment is increasingly adopted in clinical practice, this population should be a priority for future screening imaging studies.